Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Regenerative Medicines: Bone and Joint Applications

Enquire | Email | Print

Single User - $6,650       2 to 5 Users - $8,500       6 to 10 Users - $10,500       11to 20 Users - $12,500       21+ Users - $15,000
Published Date: Jun, 2013
Format: PDF
No of Pages: 290

 
 
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

REPORT HIGHLIGHTS

This report provides:

-An overview of the market for regenerative medicines in bone and joint applications, whose key objectives are the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process.
-Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
-Coverage of other regenerative applications, such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care, as well as stem cell research.
-Identification of market drivers, including an increase in diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone- and cartilage-growth-stimulating agents in a regenerative appliance.
-Descriptions of products, such as bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.

INTRODUCTION

Regenerative medicine in orthopedic applications is a $2.7 billion per year niche sector in America’s $2.6 trillion per year healthcare system. However, it is a sector of immense interest in terms of technical and medical possibilities. The best analogy to the current state of regenerative therapies in the bone and joint healing sector is the nascency of the microprocessors business back in 1971. At that time, microprocessors (namely Intel’s 4004), and related innovations, were just an infinitesimal segment of electronic component sales, but this innovation came to dominate the economy. The regenerative therapies sector, particularly areas such as cell therapy and stem cell derived products is in a comparable position today.

The regenerative medicine industry has been in existence for nearly 25 years. Actual product sales, along with research and development (R&D) expenditures, are projected to amount to approximately $2.7 billion in economic activity in 2013, of which venture capital and R&D funding accounts for about $145 million. The rapid evolution of this business is evidenced by the industry consolidation that has occurred since the first edition of this BCC Research report was published in 2003 and even since the most recent edition in 2009. Innumerable buyouts, consolidations, product abandonments, new firms and a few bankruptcies, too, have occurred in just the last several years. These changes are reflected in the Company Profiles section of this report. In addition, intensive R&D efforts at universities, the National Institutes of Health, the National Science Foundation and at FDA centers that focus on cutting–edge technology underscore the importance of this industry.

Regenerative therapies have the potential to improve medical outcomes, enhance quality of life, and reduce overall healthcare costs. A key objective is the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process. The most successful products have drawn upon multidisciplinary fields such as biology, medicine, engineering, and, particularly, biomedical engineering. The principal focus in this report is on bone and joint applications; however, other regenerative applications such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care are important and are briefly covered to underscore the larger importance of regenerative therapies. Stem–cell research is an important component of the sector as well. For example, the successful differentiation of embryonic stem cells into specific cell types is widely sought as a means to treat traumatic spinal–cord injury, as well as diseases such as diabetes, Duchenne muscular dystrophy, heart disease, and vision and hearing loss.

OBJECTIVES AND GOALS OF STUDY

This report focuses on the bone– and joint–related applications of and markets for the various categories of regenerative medicine products currently available and projected to be introduced during the five–year forecast period from 2013 through 2018. Market drivers discussed include the status of R&D and what is likely to issue from R&D in the way of actual products and therapies. Other market drivers include the incidence, and rate of growth, of diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of non–autograft products by physicians; and innovative devices that incorporate bone– and cartilage–growth–stimulating agents in a regenerative appliance. Products discussed include bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.

Profiles are provided of leading and emerging companies in the bone and joint regenerative medicine markets, along with analyses of the current and future positioning of their products and businesses in this active and rapidly changing market. Developmental and clinical stage companies are well covered.

CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE

The aim of this report is to provide an overview of regenerative medicine products, both available and emerging, for the treatment of diseases and disorders of the bones and joints. The information and analysis presented are important assets in decision making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking, and deal creation, as well as for consultants to the pharmaceutical and biotechnology industries. The study provides a comprehensive analysis of the current markets for regenerative medicine products for bones and joints, relevant applications, and the potential of products in development.

STUDY SCOPE AND FORMAT

The U.S. has been the main regenerative medicine market both in terms of R&D innovation, patents, and product sales often accounting for as much as half of the market depending on the product niche; hence, the scope of the study is mainly the U.S., although global developments are discussed and measurements provided where relevant. The Overview section provides a background of the demographics underlying the market for bone and joint products, a definition of regenerative medicine and the technologies involved, and a discussion of regenerative products in development for applications other than bones and joints. Various application sections describe the leading bone and joint diseases and disorders applicable to regenerative technologies, including incidence and current methods of treatment.

The section on Products provides extensive descriptions and analyses (e.g., comparative analysis) of regenerative products used to treat bone and joint disorders, as well as a discussion of products in development.

The section on FDA clinical trials and newly approved products provides a discussion of regulatory issues affecting regenerative medicine products.

An extensive Company Profiles section provides estimates for the revenues of the leading companies and a concise description of leading and emerging companies in the area of regenerative products for bones and joints, including product introductions, patents, and overall business strategies.

METHODOLOGY

Both primary and secondary research methodologies were used to prepare this market research report. The base year for this study is 2012. Data for 2013 are estimated and 2018 is the forecast terminal year. Sales data are estimated in nominal dollars (unadjusted for inflation). Information to prepare this study was derived from market intelligence provided by leading companies involved in the regenerative medicine market. Data was accessed from government agencies and regulatory bodies that monitor and/or regulate medical devices. Searches of secondary material such as company annual reports and 10Ks, medical journal articles, prospectus assessments, government resources, and data from healthcare institutions were conducted.

INFORMATION SOURCES

The information and analyses presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries, as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations, and national and world health organizations. 

Chapter- 1: INTRODUCTION - Complimentary 4 $0
OBJECTIVES AND GOALS OF STUDY
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE
STUDY SCOPE AND FORMAT
METHODOLOGY
INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC REPORTS
BCC ONLINE SERVICES
DISCLAIMER

Chapter- 2: SUMMARY 2 $250
Table Summary : U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2018
Figure Summary : U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2012-2018

Chapter- 3: OVERVIEW AND OVERALL STATUS OF THE INDUSTRY 13 $366
TOTAL SCOPE OF REGENERATIVE MEDICINE MARKET
ESTIMATED NUMBER OF COMPANIES IN REGENERATIVE SECTOR
SIZE OF ORTHOPEDIC SECTOR AND LEADING SUPPLIERS
HOW REGENERATIVE MEDICINE WORKS
TISSUES AND ORGANS ON DEMAND
BARRIERS TO REGENERATIVE MEDICINE
CURRENT R&D PRIORITIES
NATIONAL SCIENCE FOUNDATION PRIORITIES
TOTAL OUTPUT OF THE SECTOR
REGENERATIVE MEDICINE AND HEALTHCARE ECONOMICS
OVERSEAS INITIATIVES

Chapter- 4: PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE 13 $366
HUMAN SUBSTANCES
CELLS AND TISSUES
SETTING THE STAGE FOR REGENERATIVE MEDICINE TO TREAT BONE AND JOINT DISORDERS
BIOREACTOR USE IN REGENERATIVE MEDICINE
THE IMPACT OF GENOMICS

Chapter- 5: PRODUCTS AND TECHNOLOGIES: CATEGORIES OF REGENERATIVE MEDICINE 17 $479
GENE- AND PROTEIN - BASED APPROACHES
GROWTH FACTORS
CELLS AND TISSUES
EMBRYONIC STEM CELLS
NOVEL MATERIALS AND BIOMATERIALS

Chapter- 6: STEM CELL THERAPIES AND REGENERATIVE MEDICINE 17 $479
STEM CELLS AS POTENTIAL REPLACEMENT CELLS
OVERALL MARKET AND PARTICIPANTS
STEM CELL MARKET RISKS
TECHNICAL IMPEDIMENTS
STATE-LEVEL INITIATIVES FOR STEM CELL RESEARCH
POTENTIAL APPLICATIONS: CURRENT STATUS
GERON AND THE FIRST HUMAN TRIALS
OTHER STEM CELL RESEARCH
STATUS OF OTHER CLINICAL TRIALS

Chapter- 7: REGENERATIVE PRODUCTS TO TREAT BONE DISEASES 31 $874
REGENERATIVE PRODUCTS TO TREAT BONE DISEASES
OSTEOBIOLOGICS
BONE GRAFTS
THE MARKET FOR ALLOGRAFTS
CELL-BASED BONE GRAFT SUBSTITUTES
BONE MORPHOGENIC PROTEINS
CERAMIC-BASED BONE GRAFT SUBSTITUTES
POLYMER-BASED BONE GRAFT SUBSTITUTES
THE MARKET FOR BONE GRAFT PRODUCTS
OTHER REGENERATIVE MEDICINE PRODUCTS IN DEVELOPMENT FOR BONE APPLICATIONS
BIOCELLULAR GRAFTS

Chapter- 8: REGENERATIVE APPLICATIONS FOR BONES AND JOINTS 36 $1015
MATERIALS FOR BONE TISSUE REPAIR
INHERENT REGENERATION OF BONE
OVERALL SIZE OF BONE GRAFT BUSINESS
BONE GRAFT SUBSTITUTES
ALLOGRAFT TISSUE
OTHER OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES
HYDROGELS AND REGENERATION
MAJOR DISEASES AND CONDITIONS AFFECTING BONES
THE MARKET FOR PRODUCTS TO TREAT OSTEOPOROSIS
PAGET'S DISEASE
THE MARKET FOR PRODUCTS TO TREAT PAGET'S DISEASE
INJURIES AND DEGENERATIVE CONDITIONS
TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS
JOINT-REPLACEMENT SURGERY
KNEE REPLACEMENTS
NATURAL THERAPEUTIC TREATMENTS FOR ARTHRITIS
IMAGING MARKETS AND REGENERATIVE THERAPIES

Chapter- 9: ELECTRICAL BONE GROWTH STIMULATOR MARKET 8 $226
OVERVIEW
SCIENTIFIC BASIS
ULTRASONIC OSTEOGENESIS STIMULATORS FOR BONE HEALING
MARKETERS OF INVASIVE AND NONINVASIVE ELECTRICAL BONE GROWTH STIMULATORS
MARKET SIZE
R&D - FUTURE PRODUCT POSSIBILITIES

Chapter- 10: ORTHOPEDICS - FDA CLEARANCES AND NEW PRODUCT DEVELOPMENT 15 $423
SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS

Chapter- 11: MARKET FOR TISSUE ENGINEERING PRODUCTS 4 $113
TISSUE ENGINEERING AND CELL THERAPY
RESEARCH INITIATIVES

Chapter- 12: REGENERATIVE CONCEPTS AND PRODUCTS IN DENTISTRY 6 $169
OVERVIEW
INDICATIONS AND HISTORY
CHARACTERISTICS AND MATERIALS
DENTAL REGENERATIVE PRODUCT VENDORS

Chapter- 13: SKIN TECHNOLOGIES 3 $85
SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS
Table 43 : EXAMPLES OF FDA APPROVED HUMAN SKIN SUBSTITUTES

Chapter- 14: NEUROLOGICAL APPLICATIONS IN REGENERATIVE MEDICINE 5 $141
OVERVIEW
NEURODEGENERATIVE DISEASES
BEST PROSPECTS FOR STEM CELLS IN THIS MARKET
CURRENT CONVENTIONAL THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE SYMPTOMS
SPINAL-CORD INJURY, NEURODEGENERATIVE DISEASES, AND REGENERATIVE POTENTIAL

Chapter- 15: REGENERATIVE MEDICINE AND APPLICATIONS IN CARDIAC CARE 6 $169
OVERVIEW
GENETIC BASIS FOR REGENERATING CELLS AFTER HEART ATTACK
STEM CELLS FOR THE FUTURE TREATMENT OF HEART DISEASE
PARTICULAR R&D PRIORITIES
STEM CELLS AND BIOLOGICAL PACEMAKERS
HEART PROGENITOR CELLS DEVELOPED FROM EMBRYONIC STEM CELLS
OTHER CURRENT REGENERATIVE MEDICINE AS IT RELATES TO THE HEART

Chapter- 16: REGENERATIVE MEDICINE AND DIABETES 2 $56
BACKGROUND
POSSIBLE APPLICATIONS FOR REGENERATIVE MEDICINE
CLINICAL TRIALS

Chapter- 17: FDA APPROVED CLINICAL TRIALS INVOLVING REGENERATIVE MEDICINE 21 $592
CURRENT STATUS OF THE REGENERATIVE MEDICINE BUSINESS
REGULATORY AND LEGAL ENVIRONMENT
STATUS OF RESEARCH AND CLINICAL TRIALS
ANALYSIS OF CLINICAL TRIALS

Chapter- 18: OVERSEAS ACTIVITIES 5 $141
DOMESTIC VERSUS OVERSEAS REGENERATIVE MEDICINE COMPANIES

Chapter- 19: PATENT ANALYSIS 12 $338
ANALYSIS
TISSUE ENGINEERING PATENTS
GEOGRAPHIC DISTRIBUTION
RECENT PATENTS

Chapter- 20: COMPANY PROFILES 64 $1804
AASTROM BIOSCIENCES INC.
ADVANCED CELL TECHNOLOGY INC.
AESCULAP INC.
ALDAGEN INC.
ALPHATEC SPINE INC.
ANGIOTECH PHARMACEUTICALS INC.
ANIKA THERAPEUTICS INC.
APERION BIOLOGICS INC.
ARTERIOCYTE MEDICAL SYSTEMS INC.
ARTHREX INC.
ARTHROCARE CORPORATION
AUDAX MEDICAL INC.
BAXTER
BERKELEY ADVANCED BIOMATERIALS, INC.
BIOMATLANTE
BIOMET, INC.
BIOMIMETIC THERAPEUTICS INC.
BIOSURFACE ENGINEERING TECHNOLOGIES (BIOSET)
BIOTIME INC.
BIOTISSUE TECHNOLOGIES GMBH
CAM BIOCERAMICS B.V.
CAPSTONE THERAPEUTICS
CELLING BIOSCIENCES LLC
CENTERPULSE ORTHOPAEDICS INC.
CERAPEDICS INC.
CITAGENIX INC.
CO.DON AG
COLLPLANT LTD.
CONMED CORPORATION
CRYOLIFE, INC.
CURASAN AG
CURIS
CYTOMEDIX INC.
CYTORI THERAPEUTICS INC.
DELENEX THERAPEUTICS AG
DEPUY ORTHOPAEDICS INC. (UNIT OF THE DEPUY COMPANIES)
DISCGENICS
DJO SURGICAL
ETEX CORPORATION
EXABONE GMBH
EXACTECH, INC.
FATE THERAPEUTICS INC.
GARNET BIOTHERAPEUTICS
GEISTLICH PHARMA AG
GENZYME BIOSURGERY
GERON CORPORATION
GRAFTYS
HARVARD BIOSCIENCE
HISTOGEN
INTEGRA LIFESCIENCES HOLDING CORP.
INTELLICELL BIOSCIENCES INC.
INTERNATIONAL STEM CELL CORPORATION
INTERPORE CROSS INTERNATIONAL
ISTO TECHNOLOGIES INC.
K2M INC.
KENSEY NASH CORPORATION
KUROS BIOSURGERY AG
LIFECELL
MCEWEN CENTRE FOR REGENERATIVE MEDICINE
MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE
MEDTRONIC INC.
MESOBLAST, LIMITED
NATIONAL CENTER FOR REGENERATIVE MEDICINE
NATIONAL TISSUE ENGINEERING CENTER (NTEC)
NEURALSTEM INC.
NOVABONE PRODUCTS LLC
NOVARTIS CORPORATION
NUVASIVE
OLYMPUS BIOTECH CORPORATION
OPEXA THERAPEUTICS INC.
ORGANOGENESIS INC.
ORTHOFIX INTERNATIONAL N.V.
ORTHOPEUTICS, L.P.
ORTHOVITA INC.
OSIRIS THERAPEUTICS INC.
OSTEOGENICS BIOMEDICAL INC.
OSTEOTECH INC.
PARCELL LABORATORIES
PFIZER INC.
PLURISTEM THERAPEUTICS
PROMOCELL GMBH
REGENECURE LTD.
REGENTIS BIOMATERIALS LTD.
RENEURON
REPLACEMENT THERAPY MATERIALS (R.T. MAT.)
REPLIGEN CORPORATION
ROSLIN CELLAB
RTI BIOLOGICS INC.
SCIL TECHNOLOGY GMBH
SHIRE REGENERATIVE MEDICINE
SIGMA-ALDRICH CORPORATION
SMITH & NEPHEW
STEMCELLS INC.
STEMCOR SYSTEMS INC.
STRAUMANN USA LLC
STRYKER CORP.
SYNTHES INC.
TEKNIMED
TENGION
TEPHA INC.
TETEC TISSUE ENGINEERING TECHNOLOGIES AG
THERMOGENESIS CORP.
TIGENIX N.V.
UCB S.A. (HEADQUARTERS)
VIACYTE INC.
WAKE FOREST INSTITUTE FOR REGENERATIVE MEDICINE
WRIGHT MEDICAL GROUP INC.
ZIMMER HOLDINGS INC.
OTHER ORGANIZATIONS INVOLVED IN REGENERATIVE MEDICINE R&D
Table 50 : PUBLICLY TRADED COMPANIES IN THE REGENERATIVE MEDICINE INDUSTRY, AS OF MAY 1, 2013
Table 51 : COMPANIES ESTIMATED SALES ATTRIBUTABLE TO REGENERATIVE THERAPIES (BONE AND JOINT), 2012

Chapter- 21: GLOSSARY OF KEY TERMS IN REGENERATIVE MEDICINE BUSINESS 6 $169

List of Tables

Summary Table : U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2018
Table 1 : FUNCTIONAL ACTIVITIES WITH REGENERATIVE MEDICINE SECTOR
Table 2 : 2012 REVENUES FOR TOP SUPPLIERS OF ORTHOPEDIC PRODUCTS AND MATERIALS
Table 3 : TEN PRINCIPAL MARKET DRIVERS
Table 4 : R&D FOCUSES FOR PRINCIPAL REGENERATIVE MEDICINE
Table 5 : 20-YEAR PLANNING HORIZON FOR REGENERATIVE MEDICINE BUSINESS: LIKELY DEVELOPMENTS
Table 6 : NATIONAL SCIENCE FOUNDATION REGENERATIVE MEDICINE FUNDING PRIORITIES AS OF MAY 1, 2013
Table 7 : PRINCIPLE RESEARCH PROJECTS OF CIMIT IN THE TISSUE-ENGINEERING AND BIOMATERIALS FIELDS, 2008-2011
Table 8 : COMPANIES INVOLVED IN BONE AND JOINT STEM CELL-BASED THERAPEUTICS
Table 9 : COMMERCIAL SUPPLIERS OF BIOREACTORS FOR USE IN REGENERATIVE MEDICINE
Table 10 : BONE MORPHOGENETIC PROTEINS
Table 11 : TOTAL U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2018
Table 12 : FEDERAL FUNDING FOR STEM CELL RESEARCH THROUGH 2012
Table 13 : STATE LEVEL PROGRAMS FOCUSED ON STEM CELL RESEARCH
Table 14 : CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL
Table 15 : U.S. BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, THROUGH 2018
Table 16 : U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2018
Table 17 : BONE GRAFT MATERIALS
Table 18 : SUBSTITUTE BONE GRAFTS
Table 19 : SELECTED DBM PRODUCTS AND PERCENTAGE OF DEMINERALIZED BONE MATRIX
Table 20 : TOTAL U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2018
Table 21 : TOTAL GLOBAL MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2018
Table 22 : U.S. MARKET FOR BONE–REPLACEMENT PRODUCTS, THROUGH 2018
Table 23 : EXAMPLES OF NANOSTRUCTURED BIOMATERIALS USEFUL IN BONE AND JOINT REGENERATION
Table 24 : DRUGS USED TO TREAT OSTEOPOROSIS
Table 25 : GLOBAL MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2018
Table 26 : TOTAL GLOBAL MARKET FOR DRUGS TO TREAT PAGET’S DISEASE, THROUGH 2018
Table 27 : TOTAL GLOBAL HIP FRACTURE VOLUMES THROUGH 2018
Table 28 : TOTAL U.S. HIP FRACTURE VOLUMES THROUGH 2018
Table 29 : U.S. MARKET SHARES FOR MUSCULOSKELETAL PRODUCTS, 2012
Table 30 : U.S. RECONSTRUCTIVE DEVICE MARKET, 2012
Table 31 : U.S. HIP REPLACEMENT PROCEDURE VOLUMES, THROUGH 2018
Table 32 : HISTORICAL RATES OF HIP REPLACEMENT IN SIX MAJOR STATES, 2001
Table 33 : GLOBAL HIP REPLACEMENT MARKET, THROUGH 2018
Table 34 : TOTAL U.S. HIP REPLACEMENT MARKET, THROUGH 2018
Table 35 : TOTAL GLOBAL KNEE-REPLACEMENT PROCEDURE VOLUMES, THROUGH 2018
Table 36 : TOTAL U.S. KNEE REPLACEMENT PROCEDURE VOLUMES, THROUGH 2018
Table 37 : TOTAL GLOBAL KNEE REPLACEMENT MARKET THROUGH 20181
Table 38 : TOTAL U.S. KNEE REPLACEMENT MARKET THROUGH 2018
Table 39 : TOTAL U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT THROUGH 2018
Table 40 : GLOBAL MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2018
Table 41 : U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2018
Table 42 : RECENTLY APPROVED ORTHOPEDIC BONE AND JOINT DEVICES BY PRODUCT, COMPANY, AND APPROVAL DATE, 2008-2012
Table 43 : EXAMPLES OF FDA APPROVED HUMAN SKIN SUBSTITUTES
Table 44 : TOTAL SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2018
Table 45 : REGENERATIVE MEDICINE CLINICAL TRIALS BY MAJOR CATEGORY
Table 46 : CURRENT CLINICAL TRIALS IN THE FIELD OF REGENERATIVE MEDICINE STATUS, CONDITIONS AND SPONSOR
Table 47 : PROJECTED REVENUES OF REGENERATIVE AND TISSUE ENGINEERING MARKETS IN JAPAN, 2009 AND 2020
Table 48 : TOP PATENT ASSIGNEES IN TISSUE ENGINEERING FIELD
Table 49 : WORLD DISTRIBUTION OF REGENERATIVE MEDICINE PATENTS ISSUED 1985-2012
Table 50 : PUBLICLY TRADED COMPANIES IN THE REGENERATIVE MEDICINE INDUSTRY, AS OF MAY 1, 2013
Table 51 : COMPANIES ESTIMATED SALES ATTRIBUTABLE TO REGENERATIVE THERAPIES (BONE AND JOINT), 2012

List of Figures

Summary Figure : U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2012-2018

Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 406705, price: INR 405010, BCC Research

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online